Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer

The mTORC1 inhibitor RAD001 (everolimus) is approved for treatment of recurrent/metastatic estrogen receptor (ER)-positive breast cancer in combination with the aromatase inhibitor (AI) exemestane. The benefits of A) continued anti-estrogen therapy for anti-estrogen-resistant disease in the context...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wei, Schwartz, Gary N., Marotti, Jonathan D., Chen, Vivian, Traphagen, Nicole A., Gui, Jiang, Miller, Todd W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823630/
https://www.ncbi.nlm.nih.gov/pubmed/29507656
http://dx.doi.org/10.18632/oncotarget.24256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823630/
https://www.ncbi.nlm.nih.gov/pubmed/29507656
http://dx.doi.org/10.18632/oncotarget.24256

Ejemplares similares